Clinical Data

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

In what Merck describes as “early signs of promising anti-tumor activity,” the PD-1xVEGF bispecific, coded MK-2010, induced an unconfirmed ORR of 55%.

Angus Liu Apr 17, 2026 3:00pm

RyghtAI launches clinical trial site search engine

Apr 16, 2026 2:35pm

Graphic image of puzzle pieces missing from a persons brain a symbol of degeneration andor the improvement of it

Fierce Pharma

Anti-amyloid Alzheimer's drugs show 'trivial' effects: report

Apr 16, 2026 11:36am

Close up of male doctor holding clipboard while talking to patients waiting in line at medical clinic

Rare Disease Research, myTomorrows partner on trial access

Apr 16, 2026 9:00am

Spyre touts ph. 2 UC win as proof it could surpass Entyvio

Apr 13, 2026 9:55am

cancer target detection radiopharma radio

Revolution’s RAS inhibitor hits key goals in ph. 3 cancer trial

Apr 13, 2026 8:00am